Transdermal Drug Delivery System Market - Upcoming Trends | Global Industry Dynamics

The report “Transdermal Drug Delivery System Market by Type (Patches and Semisolid formulations), Applications (Pain Management, Central Nervous System Disorders, Hormonal Applications, Cardiovascular Diseases), End User, and Region - Global Forecast to 2023", The transdermal drug delivery systems market is expected to reach USD 7.1 billion by 2023 from an estimated USD 5.7 billion in 2018, at a CAGR of 4.5% during the forecast period (2018-2023).

Market growth is largely driven by the global increase in the prevalence of chronic diseases. In addition, technological advancements in transdermal drug delivery systems are also expected to support market growth in the coming years.

The study involved four major activities to estimate the current market size for transdermal drug delivery systems. Exhaustive secondary research was done to collect information about the market, peer markets, and the parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across value chain through primary research. Thirdly, both top-down and bottom-up approaches were employed to estimate the complete market size. Finally, the market breakdown and data triangulation was used to estimate the market size of segments and subsegments.

Download PDF Brochure@

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=203190114

The transdermal patches segment is expected to grow at the highest CAGR during the forecast period

On the basis of type, the transdermal drug delivery systems market is segmented into transdermal patches and transdermal semisolids. In 2018, the transdermal patches segment is expected to account for the larger share of the transdermal drug delivery systems market. This drug delivery system offers several advantages, such as reduced dosing frequency, improved bioavailability, reduced adverse events, and drug input termination at any point by the removal of the patch. Also, the use of patches results in increased patient compliance due to their non-invasive nature and painless application. These factors are expected to drive market growth.

Market Size Estimation:

Top-down and bottom-up approaches were used to validate the size of the transdermal drug delivery systems market and estimate the size of other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

# The key players in the industry and markets have been identified through extensive secondary research.

# The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes.

# All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

The pain management segment is expected to account for the largest share of the market in 2018

On the basis of application, the market is segmented into pain management, central nervous system disorders, hormonal applications, cardiovascular diseases, and other applications (smoking cessation, motion sickness, and overactive bladder treatment). In 2018, the pain management segment is expected to account for the largest share of the transdermal drug delivery systems market. Growth in this market is largely driven by the high burden of chronic pain worldwide and the growing availability of transdermal products for pain management.

Key Questions addressed by the report:

# Which are the key players in the market and how intense is the competition?

# Emerging countries have immense opportunities for the growth of transdermal drug delivery systems market, will this scenario continue?

# Which product market will dominate in future?

# What does the future look like for transdermal drug delivery systems?

# What are the challenges hindering the adoption of transdermal drug delivery systems?

Request Sample Pages@

https://www.marketsandmarkets.com/requestsampleNew.asp?id=203190114

Global Leaders of the Industry:

Hisamitsu Pharmaceutical (Japan), Mylan (US), UCB (Belgium), Novartis (Switzerland), GlaxoSmithKline (UK), Abbvie (US), Boehringer Ingelheim (Germany), Johnson & Johnson (US), Endo International (Ireland), and Purdue Pharma (US) are the major players operating in the global transdermal drug delivery systems market.

These players have adopted various growth strategies, such as product launches and enhancements; agreements, partnerships, mergers, and collaborations; acquisitions; and expansions to strengthen their presence in the global market. Product launches and partnerships have been the most widely adopted strategies by major players from 2015 to 2018. These strategies helped market players to offer innovate products and broaden their customer base.

Transfection Reagents and Equipment Market - Global Leaders and Growth Strategies Adopted by Them

The global growth of the transfection reagent market can be attributed to factors such as advancements in transfection technology, global alliances among leading research institutes to trigger drug discovery, increase in R&D spending and research activities by pharmaceutical and biotechnology companies, increase in demand for synthetic genes, and rising incidence of cancer.

Moreover, development of large scale transfections, rising demand of protein therapeutics, and emerging markets across India and China are likely to create opportunities for players operating in the market.

The global transfection reagent market includes forecast from 2016 to 2021. This market is expected to reach USD 1.02 Billion by 2021 from USD 715.4 Million in 2016, at a CAGR of 7.5% during the forecast period.

The global transfection equipment market is segmented on the basis of product, method, application, end user, and region. Based on product, the market is segmented into reagents and instruments. In 2016, the reagents segment is estimated to account for the largest share of the market. However, the instruments segment is expected to grow at the highest CAGR during the forecast period.

Download PDF Brochure@

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=139141146

Major Leaders:

The overall market was dominated by Thermo Fisher Scientific Inc. (U.S.), Promega Corporation (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), and QIAGEN N.V. (Netherlands). Other players include Polyplus-transfection SA (France), Bio-Rad Laboratories Inc. (U.S.), Lonza Group (Switzerland), Sigma-Aldrich Corporation (U.S.), Mirus Bio LLC (U.S.), and MaxCyte, Inc. (U.S.).

Growth Strategies Adopted by Them:

The key players in this market are continuously striving to gain larger shares and expand their existing product portfolios by agreements, collaborations, and partnerships.

Thermo Fisher Scientific Inc. (U.S.) is leading player in the transfection reagents and equipment market with a market share of ~61.5% in 2015. The company primarily focuses on growth strategies such as acquisitions to add innovative technologies and products to its portfolio, which in turn helps the company to strengthen its presence in the respective markets.

Thermo Fisher acquired Affymetrix, Inc. (U.S.) in 2016, Advanced Scientifics, Inc. (U.S.) in 2015, and Life Technologies Corporation (U.S.) in 2014. This helped the company to expand its customer base and significantly boost its market share. The company’s major share in the transfection reagents and equipment market can be attributed to its broad product portfolio, years of experience, and extensive distribution channel.

Target Audience:

# Biopharmaceutical companies

# Biotechnology companies

# Transfection equipment, reagent, and kit manufacturing companies

# Suppliers and distributors of transfection reagents

# Research institutes

# Academic centers

# Venture capitalists

Promega Corporation (U.S.) is another dominant player in the transfection reagents and equipment market. The company accounted for approximately ~17.4% of the market revenue generation. The firm offers more than 3000 products for life science research, particularly in genomics, protein analysis and expression, cellular analysis, drug discovery, and genetic identity. It offers various transfection reagents under its reporter assays and transfection category of products.

Promega has branches in 16 countries with more than 50 global distributors. The company possesses a strong intellectual property portfolio, which helps it to maintain its position in the life science market. Promega owns more than hundred patents in the field of nucleic acid purification, human identification, bioluminescence, coupled in vitro transcription and translation, and cell biology. The company focuses on the strategy of new product development and expansion to strengthen its position in the market.

Request Sample Pages@

https://www.marketsandmarkets.com/requestsampleNew.asp?id=139141146

Players operating in the transfection reagents and equipment market adopted strategies such as agreements, collaborations, and partnerships to strengthen their global presence.

The key players that have adopted these strategies include MaxCyte, Inc. (U.S.), Polyplus-transfection SA (France), QIAGEN N.V. (Netherlands), Lonza Group Ltd. (Switzerland), F. Hoffmann-La Roche ltd (Switzerland), and Thermo Fisher Scientific Inc. (U.S.)

Global Electroceuticals Industry is Expecting Major Spike in Revenue in Near Future

This report studies the global Electroceuticals Market for the forecast period of 2016 to 2021. This market is expected to reach USD 25.20 Billion by 2021 from USD 17.20 Billion in 2016, at a CAGR of 7.9%.

A number of factors such as rising geriatric population, regulatory approval for new and advanced electroceuticals, growing investments and funds for the development of novel therapies and electroceuticals, rising prevalence of neurological disorders, and growing prevalence of hearing loss are expected to drive the growth of the electroceuticals/bioelectric medicine market during the forecast period.

In this report, the global electroceuticals/bioelectric medicine market is segmented on the basis of product, type of device, application, end user, and region.

Target Audience:

# Electroceuticals/Bioelectric Medicine Device Manufacturing Companies

# Suppliers and Distributors of Electroceutical/Bioelectric Medicine Devices

# Healthcare Service Providers

# Teaching Hospitals and Academic Medical Centers (AMCs)

# Health Insurance Players

# Research and Consulting Firm

# Medical Research Institutes

# Audiology Centers

# Healthcare Institutions/Providers

Download PDF Brochure@ 

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=222053956

Based on application, the electroceuticals/bioelectric medicine market is segmented into product wise such as cardiac pacemakers and implantable cardioverter defibrillators, cochlear implants, retinal implants, spinal cord stimulators, deep brain stimulators, sacral nerve stimulators, vagus nerve stimulators, transcutaneous electrical nerve stimulators, and other electric stimulators.

Based on type of device, the electroceuticals/bioelectric medicine market is segmented into implantable electroceutical devices, and non-invasive electroceutical devices. The implantable electroceutical devices segment is expected to account for the largest share of the market in 2016; while, the non-invasive electroceutical devices segment is projected to grow at the highest CAGR in the forecast period.

Objectives of the Study:

# To define and measure the global electroceuticals market with respect to product, type of device, application, end user and region.

# To identify key micromarkets and their drivers within the global electroceuticals market, which are expected to show growth opportunities in the coming years.

# To analyze opportunities in the bioelectric medicine market for stakeholders and provide details of the competitive landscape for market leaders.

# To analyze the market structure and profile the key players of the global electroceuticals medicine market and comprehensively analyze their core competencies.

# To track and analyze competitive developments such as product launches, approvals, agreements/collaborations/joint ventures/partnerships, marketing and promotion activities, acquisitions and mergers, expansions, new program launches, and product enhancements.

On the basis of end user, the electroceuticals/bioelectric medicine market is segmented into hospitals, research institutes, and individual users. The hospitals segment is expected to account for the largest share of the market in 2016; while, the individual users segment is projected to grow at the highest CAGR in the forecast period.

Geographical Scenario:

Geographically, the global electroceuticals/bioelectric medicine market is divided into North America, Europe, Asia-Pacific, and the Rest of the World (Latin America, Middle East, and Africa). North America is expected to account for the largest share of the electroceuticals/bioelectric medicine market in 2016, followed by Europe, Asia-Pacific, and the Rest of the World. The Asia-Pacific market is projected to grow at the highest CAGR, and serves as a revenue pocket for companies offering electroceuticals/bioelectric medicine devices.

Request Sample Pages@

https://www.marketsandmarkets.com/requestsampleNew.asp?id=222053956

Major Industry Leaders:

The electroceuticals/bioelectric medicine market is dominated by various companies including Medtronic plc (Ireland), St. Jude Medical, Inc. (U.S.), Boston Scientific Corporation (U.S.), Cochlear Limited (Australia), Sonova Holding AG (Switzerland), LivaNova PLC (U.K.), Biotronik (Germany), Nevro Corporation (U.S.), Second Sight Medical Products, Inc. (U.S.), and ElectroCore LLC (U.S.). Some of the other players in the market are BioElectronics Corporation (U.S.), MED-EL (Austria), Cefaly Technology (Belgium), Stimwave LLC (U.S.), Vomaris Innovations, Inc. (U.S.), EnteroMedics Inc. (U.S.), NeuroSigma, Inc. (U.S.), and Oticon Medical (France).

Major Growth Strategies Adopted by Major Leaders:

Product launches, approvals, new product launches, agreements/collaborations/joint ventures/partnerships, marketing and promotion activities, acquisitions and mergers, expansions, and other strategies (including market developments, new program launches, and product enhancements) are major strategies adopted by players to achieve growth in the electroceuticals/bioelectric medicine market.

Respiratory Care Devices Market is Expecting Major Revenue Growth by 2025

The global respiratory care devices Market is expected to reach USD 29.9 billion by 2025 from USD 16.0 billion in 2019, at a CAGR of -12.5% during the forecast period of 2020 to 2025. Due to the outbreak of coronavirus globally, there is a sudden rise in the demand for respiratory care devices. Thus, the respiratory care devices market witnessed a CAGR of 261.1% between 2019 and 2020. 

In 2020, the respiratory care devices market reached USD 58.1 billion. The growth of this market is mainly attributed to the high prevalence of respiratory diseases, rising aging population across the globe, high prevalence of smoking, rising urbanization and pollution levels, increasing incidence of preterm births, and lifestyle changes. 

However, a lack of awareness leading to a large underdiagnosed and undertreated population and the harmful effects of specific respiratory care devices on neonates have hampered market growth to an extent. 

Download PDF Brochure@

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=368

Objectives of the Study:

# To define, describe, and forecast the respiratory care devices market based on type, indication, end user, and region.

# To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges).

# To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the total market

# To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders.

# To forecast the size of the market segments with respect to five major regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

# To profile key market players and comprehensively analyze their product portfolios, market shares, and core competencies.

# To track and analyze competitive developments, such as product launches, expansions, acquisitions, agreements, and collaborations in the respiratory care devices market.

The hospitals segment accounted for the largest market share in 2019

Based on the end-user, the respiratory care devices market is segmented into hospitals, home care settings, and ambulatory care centers. In 2019, hospitals accounted for the largest market share. 

Their financial capabilities, which allow them to purchase expensive instruments, and the availability of trained professionals to operate these instruments, have ensured the high percentage of hospitals in this market. Home care settings are expected to witness the highest growth during the forecast period, mainly due to the development of compact and lightweight respiratory care devices that are easier to carry and operate.

Recent Developments:

# In April 2020, Philips launched the PHILIPS RESPIRONICS E30 VENTILATOR. This will enable company to help healthcare professionals by providing superior quality ventilators.

# In January 2020, Masimo Corporation acquired Connected Care Business from NantHealth (US). This acquisition will support Masimo to assist hospitals in providing constant care through connectivity, automation, and innovative noninvasive monitoring technologies.

# In May 2020, Philips did partnership with Masimo. This partnership was aimed at integrating Masimo’s measurement technologies into select intellivue MX-Series multi-parameter monitors to help clinicians examine ventilation status and cerebral oximetry.

# In March 2019, ResMed acquired HB Healthcare Safety, a provider of home-based medical equipment for sleep and respiratory care devices.

North America was the largest regional market forbioanalytical testing services in 2019

The global bioanalytical testing services market is segmented into five major regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2019, North America accounted for the largest share of the market. The large share of North America region is mainly attributed to the strong presence of a large number of major manufacturers, its rising geriatric population, high prevalence of smoking and respiratory diseases, and the presence of a highly developed healthcare system.

Request Sample Pages@

https://www.marketsandmarkets.com/requestsampleNew.asp?id=368

The prominent players operating in this market include Philips Healthcare (Netherlands), ResMed Inc. (US), Medtronic plc (Ireland), Masimo Corporation (US), Fisher & Paykel Healthcare (New Zealand), Drager AG (Germany), Invacare Corporation (US), Nihon Kohden (Japan), Getinge AB (Sweden), Air Liquide (France), Invacare Corporation (US), Vyaire Medical (US), GE Healthcare (US), Nonin Medical Inc. (US), Apex Medical Corp. (Taiwan), Smiths Group (UK), Omron Healthcare Inc. (US), Allied Healthcare Products, Inc. (US), Teleflex Incorporated (US), Drive DeVilbiss Healthcare (US), 3B Medical, Inc. (US), Medline Industries, Inc. (US), Acare Technology Co. (Taiwan), Hill-Rom Holdings, Inc. (US), and Rotech Healthcare, Inc. (US).

These players adopted the strategies of partnerships, agreements,and acquisitions to expand their presence in the global respiratory care devices market.

Specimen Retrieval Market is Expecting Major Growth, Globally..!

The study involved four major activities in estimating the current size of the Specimen Retrieval Market. Exhaustive secondary research was conducted to collect information on the market and its subsegments. The next step was to validate these findings, assumptions, and sizing estimates with industry experts across the value chain through primary research.

Both top-down and bottom-up approaches were employed to estimate the complete market size. Thereafter, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.

The specimen retrieval systems market is expected to grow from USD 230 million in 2019 to USD 290 million by 2024, at a compound annual growth rate (CAGR) of 4.7% during the forecast period.

The major factors driving the growth of this market include the increasing prevalence of diseases requiring surgical treatment and removal of specimens from the body, especially laparoscopic procedures.

Market Size Estimation:

Both top-down and bottom-up approaches were used to estimate and validate the total size of the specimen retrieval systems market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

# The key players in the industry and markets have been identified through extensive secondary research.

# The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes.

# All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

Download PDF Brochure@

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=126359758

Hospitals were the largest end users of specimen retrieval systems in 2018

By end user, the specimen retrieval systems market is segmented into hospitals and other end users. The hospitals segment accounted for the largest market share in 2018 and is expected to register the highest growth during the forecast period. The large share and high CAGR of this segment can be attributed to the robust infrastructure and presence of skilled professionals in hospitals, which has driven the preference for hospital-based treatment.

Major Objectives Behind This Study:

# To define, describe, and forecast the specimen retrieval systems market by type, introducer size, application, end user, and region.

# To forecast the revenue of the market segments with respect to four main regional segments, namely, North America, Europe, Asia Pacific, and the Rest of the World (RoW).

# To identify the micromarkets with respect to drivers, industry-specific challenges, opportunities, and trends affecting the growth of the market.

# To analyze market segments and subsegments with respect to individual growth trends, prospects, and contributions to the overall market.

# To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders.

# To profile the key players and comprehensively analyze their market shares and core competencies, in terms of market developments and growth strategies.

# To track and analyze competitive developments such as partnerships, agreements, collaborations, acquisitions, product launches, and R&D activities in the specimen retrieval systems market.

Gastrointestinal surgeries held the largest share of the applications market in 2018

Based on applications, the specimen retrieval systems market is segmented into gastrointestinal surgeries, urological surgeries, gynecological surgeries and other applications such as cardiovascular and bariatric surgeries. In 2018, the gastrointestinal surgeries application segment accounted for the largest share of the specimen retrieval systems market. The large share of this segment can be attributed to the increasing incidence of colon/gastrointestinal cancer, inguinal hernia, and gall bladder stones.

Recent developments:

# In 2018, Genicon, Inc. entered into a distribution agreement with Greenpine Pharma, China to distribute its complete range of products in China.

# In 2017, B. Braun opened five new production and administration facilities in Penang to cater to end users in Malaysia. The company aims to manufacture medical devices for infusion therapy, pharmaceutical solutions, and surgical instruments in these facilities.

Request Sample Pages@

https://www.marketsandmarkets.com/requestsampleNew.asp?id=126359758

North America commanded the largest share of the specimen retrieval systems market in 2018

North America dominates the specimen retrieval systems market. The large share of North America in this market can be attributed to the increasing incidence and prevalence of cancer, hernia, and appendectomy and the availability of reimbursement for laparoscopic surgeries in the region.

The specimen retrieval systems market is highly consolidated in nature, with a few players offering a variety of products. The major players operating in this market are Johnson & Johnson Services, Inc. (US), Teleflex Incorporated (US), Applied Medical Resources Corporation (US), CONMED Corporation (US), Cooper Surgical, Inc. (US), Genicon (US), B. Braun Melsungen AG (Germany), Laprosurge (UK), Purple Surgical (UK), and Medtronic (Ireland).

The key growth strategies followed by most companies in the specimen retrieval systems market are acquisitions and agreements. These two strategies accounted for the largest share of the overall growth strategies mapped from 2015 to 2018.

Healthcare Cloud Computing Market - Emerging Industry Trends and Global Future Forecasts

This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.

The report “Healthcare Cloud Computing Market by Product (EMR/EHR, PACS, VNA, PHM, Telehealth, RCM, CRM, Fraud Management), Service (SaaS, IaaS), Deployment (private cloud, hybrid cloud), Pricing (Pay as you go), Component (Software) - Global Forecast to 2024", The global healthcare cloud computing market size is projected to reach USD 51.9 billion by 2024, from an estimated USD 23.4 billion in 2019 at a CAGR of 17.2 % during the forecast period.

The growth of this market is primarily attributed to the increasing adoption of big data analytics, wearable devices, and IoT in healthcare and the advantages of cloud usage, such as improved storage, flexibility, and scalability of data.

Critical Questions Answered in the Report:

# How will the current technological trends affect the healthcare cloud computing market in the long term?

# What are the reasons contributing to the growth of the provider and payer solutions in the market?

# Which regions are likely to grow at the highest CAGR in the global market?

# What are the challenges hindering the adoption of healthcare cloud computing in the market?

# What are the growth strategies being implemented by major market players?

Download PDF Brochure@

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=347

Based on the product, the healthcare cloud computing industry is segmented into healthcare providers solutions and healthcare payer solutions. The healthcare providers solutions accounted for the largest share of the global healthcare cloud computing market in 2018. The large share of this segment can be attributed primarily to the growing population and rising prevalence of diseases, leading to an increasing volume of patient data globally.

The healthcare provider solutions market is segmented into two different types, i.e., clinical information systems and non-clinical information systems. The clinical information systems market accounted for the majority of the global healthcare cloud computing market share in 2018. The large share of this segment can be attributed to the federal mandates to adopt EMR, growing image generation, and the need for scalability and easy sharing of medical information, growing need to curtail healthcare costs in combination with advantages of cloud hosting such as affordability and scalability.

Recent Developments:

# In 2019, NTT DATA and Google Cloud announced a joint go-to-market strategy to provide consulting, implementation, and managed services to clients seeking digital transformation. Google Cloud enhanced NTT DATA’s cloud transformation offerings by adding more Google Cloud resources in analytics, artificial intelligence, machine learning, cloud migration, IoT, security, and productivity.

# In 2019, IBM acquired Red Hat, which is a landmark acquisition for USD 34 billion. The addition will enhance IBM’s hybrid cloud portfolio and aim to develop a next-generation multi-cloud hybrid platform.

# In 2018, DXC Technologies acquired TESM (UK) to expand the range of cloud-based solutions and enterprise software as a service solution. This enabled DXC to address customer needs across the Europe region.

By pricing model, the pay-as-you-go segment accounted for the largest share of the market in 2018

Based on the pricing model, the market is categorized into pay-as-you-go and spot pricing. The pay-as-you-go segment commanded the largest share of the healthcare cloud computing market in 2018. The large share of this segment can be attributed to the fact that the pay-as-you-go model allows healthcare providers to provide the latest software solutions while keeping operating costs to a minimum. This helps healthcare providers not to lock-in their capital on purchasing equipment, such as CPUs and servers, but utilizing all these services on an on-demand basis by paying only for what they use.

By service model, the software-as-a-service segment accounted for the largest share of the market in 2018

Based on the service model, the market is categorized into software-as-a-service, infrastructure-as-a-service, and platform-as-a-service. The software-as-a-service segment commanded the largest share of the healthcare cloud computing market in 2018. The large share of this segment can be attributed to the fact that SaaS was introduced in the market well in advance of the other two models. Additionally, the SaaS model offers several advantages, such as lower total cost of ownership (TCO) compared to on-premise solutions, faster deployment time, and limited up-front capital expenses. The IaaS segment is expected to grow at the highest CAGR owing to its advantages, such as needing any upfront charges, bandwidth utilization fees, or minimum term commitments.

Request Sample Pages@

https://www.marketsandmarkets.com/requestsampleNew.asp?id=347

North America dominated the market in 2018

In 2018, North America accounted for the largest share of the global healthcare cloud computing market, followed by Europe. Factors such as the increasing adoption of Electronic Health Records (EHRs) among medical professionals, the incentive-driven approach of government health IT programs, and active participation by private sector players in industry development contribute to the largest share of this region.

Some players operating in the global healthcare cloud computing market include IBM (US), Carestream Health, Inc (US), athenahealth (US), CareCloud Corporation (US), Siemens Healthineers (Germany), eClinicalWorks (US), Koninklijke Philips (Netherlands), Allscripts Healthcare Solutions, Inc (US), GE Healthcare (US), and Dell, Inc. (US), among others.

Protein Binding Assays Market - Forthcoming Trends | Major Leaders

The report “Protein Binding Assays Market by Technology (Equillibrium Dialysis, Ultrafiltration, Ultracentrifugation, Gel Filtration Chromatography), End User (Pharmaceutical & Biotechnology Companies, Contract Research Organization) - Global Forecast to 2023", The global protein binding assays market is projected to reach USD 425.7 million in 2023 from USD 256.1 million in 2018, at CAGR of 10.7%.

The increasing use of protein binding assays in pre-clinical research for studying the distribution properties of the drug, and the growing number of drug discovery activities, the minimizing drug discovery and development costs, and the increase in pharmaceutical R&D expenditure is driving the growth of this market.

Based on technology, equilibrium dialysis segment is expected to grow at the highest CAGR in the market during the forecast period

On the basis of technology, the global protein binding assays market is divided into equilibrium dialysis, ultrafiltration, ultracentrifugation, and other technologies. In 2018, the equilibrium dialysis segment is expected to grow at the highest CAGR in the protein binding assays market. The growth can be attributed to the technique’s physical simplicity, low cost, and high accuracy. It is also considered as a gold standard technique for protein binding studies.

Download PDF Brochure@

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=44025612

Based on end user, Contract Research Organizations (CROs) segment is expected to grow at the highest CAGR in the market during the forecast period

On the basis of end user, the global protein binding assays market is divided into pharmaceutical and biotechnology companies, CROs, and other end users. In 2018, the CROs segment is expected to grow at the highest CAGR in the global protein binding assays market. This high growth can be attributed to the increase increased protein binding studies for drug discovery & development by pharmaceuticals and the growing focus of biotechnology companies on developing biologics.

Target Audience:

# Government and academic institutes

# Protein binding assay providers

# R&D departments

# Contract research organizations

# Pharmaceutical & biotechnology companies

# Consulting firms

# Government associations

Asia Pacific is expected to grow at the highest CAGR during the forecast period

The APAC market is projected to register the highest growth rate during the forecast period primarily due to factors such as, growth of clinical trial activities in several APAC countries. As a result of this, the pharmaceutical and biopharmaceutical companies are outsourcing their drug discovery and development activities to APAC-based CROs. This is one of the major factors driving the growth of the protein binding assay market in the Asia Pacific.

Objectives of the Study:

# To define, describe, and forecast the protein binding assay market on the basis of technology, end user, and regions.

# To provide detailed information about factors influencing market growth (drivers, restraints, opportunities, and industry-specific challenges).

# To strategically analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall market.

# To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players.

# To forecast the size of the market segments with respect to four major regional segments, namely, North America, Europe, Asia Pacific, and the Rest of the World (RoW).

# To profile the key players in the market and comprehensively analyze their market positions and core competencies.

# To track and analyze competitive developments such as partnerships, agreements, and joint ventures; mergers and acquisitions; product development; and research and development activities in the protein binding assay market.

Request Sample Pages@

https://www.marketsandmarkets.com/requestsampleNew.asp?id=44025612

Market Players

The key players in the global protein binding assays market are HTDialysis (US), Thermo Fisher Scientific (US), Merck (Germany), and Sovicell (Germany).

Most companies focus on agreements, collaborations, and partnerships to compete in the market. The players also focus on increasing their presence in high-growth markets through acquisitions and product launches. Thermo Fisher (US), Sovicell (Germany) and 3B Pharmaceutical focus on partnerships, collaboration and license agreements to strengthen their position in the market.